Q1 2025 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2025-05-06 · accession 0000950123-25-004066
$165.9M
Reported value
9
Positions
2025-03-31
Period end
The Brief · Sanofi (SNY, SNYNF) · Q1 2025
AI · grounded in 13F
Sanofi (SNY, SNYNF) reported no changes to its 13F holdings for 2025-03-31 relative to 2024-12-31.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $82.7M | 49.8% | 12,197,737 | Common | SOLE |
| 670002401 | NVAX | Novavax | $44.1M | 26.6% | 6,880,481 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $16.2M | 9.76% | 1,157,926 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $15.3M | 9.21% | 821,917 | Common | SOLE |
| 28617K101 | ELDN | Eledon | $2.8M | 1.66% | 814,980 | Common | SOLE |
| N51517105 | 4PKB | LAVA Therapeutics N.V. | $2.4M | 1.47% | 1,919,455 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences | $1.7M | 1.00% | 1,438,975 | Common | SOLE |
| 45790W108 | — | Inozyme, Inc | $403,362 | 0.24% | 443,255 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $402,737 | 0.24% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.